{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:13:01Z","timestamp":1767665581949},"reference-count":27,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1742,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1365-2710.2010.01224.x","type":"journal-article","created":{"date-parts":[[2010,11,24]],"date-time":"2010-11-24T13:20:07Z","timestamp":1290604807000},"page":"673-679","source":"Crossref","is-referenced-by-count":6,"title":["Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition"],"prefix":"10.1155","volume":"36","author":[{"given":"Y.","family":"Baran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Zencir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Cakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Topcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2010,11,24]]},"reference":[{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB1|cit1","first-page":"161","article-title":"Imatinib mesylate and the management of chronic myeloid leukemia (CML)","volume":"2","author":"Koca","year":"2005","journal-title":"Turkish Journal of Hematology"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/10245330701384179","article-title":"Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells","volume":"12","author":"Baran","year":"2007","journal-title":"Hematology"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1471-4914(02)02305-5","article-title":"STI571 (Gleevec) as a paradigm for cancer therapy","volume":"8","author":"Druker","year":"2002","journal-title":"Trends in Molecular Medicine"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/14656566.9.7.1211","article-title":"Imatinib mesilate for the treatment of gastrointestinal stromal tumour","volume":"9","author":"Cassier","year":"2008","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11523-008-0101-x","article-title":"Imatinib in the treatment of solid tumours","volume":"4","author":"Duffaud","year":"2009","journal-title":"Targeted Oncology"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"10922","DOI":"10.1074\/jbc.M610157200","article-title":"Alterations of ceramide\/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells","volume":"282","author":"Baran","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14756360290011744","article-title":"Flavonoids as DNA topoisomerase I poisons","volume":"17","author":"L\u00f3pez-L\u00e1zaro","year":"2002","journal-title":"Journal of Enzyme Inhibition and Medicinal Chemistry"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/14756360310001613085","article-title":"Curcumin as a DNA topoisomerase II poison","volume":"18","author":"Mart\u00edn-Cordero","year":"2003","journal-title":"Journal of Enzyme Inhibition and Medicinal Chemistry"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.4161\/cbt.5.12.3546","article-title":"A review of topoisomerase inhibition in lung cancer","volume":"5","author":"Chhatriwala","year":"2006","journal-title":"Cancer Biology and Therapy"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.bmcl.2005.11.044","article-title":"Design, synthesis, and evaluation of novel 6-chloro-\/fluorochromone derivatives as potential topoisomerase inhibitor anticancer agents","volume":"16","author":"Ishar","year":"2006","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13880200600685972","article-title":"Inhibitory activities of Helichrysum taxa on mammalian type I DNA topoisomerase","volume":"44","author":"Kucukoglu","year":"2006","journal-title":"Pharmaceutical Biology"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.18388\/abp.2007_3229","article-title":"1H-Benzimidazole derivatives as mammalian DNA topoisomerase I inhibitors","volume":"54","author":"Alpan","year":"2007","journal-title":"Acta Biochimica Polonica"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1515\/znc-2008-1-213","article-title":"Flavonoids in Helichrysum pamphylicum inhibit mammalian type I DNA topoisomerase","volume":"63","author":"Topcu","year":"2008","journal-title":"Zeitschrift f\u00fcr Naturforschung C"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1023\/A:1026493310144","article-title":"The yeast two-hybrid system and its pharmaceutical significance","volume":"17","author":"Topcu","year":"2000","journal-title":"Pharmaceutical Research"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.bi.65.070196.003223","article-title":"DNA topoisomerases","volume":"65","author":"Wang","year":"1996","journal-title":"Annual Review of Biochemistry"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB19|cit19","first-page":"1","volume-title":"DNA topoisomerase II-catalyzed DNA decatenation","author":"Osheroff","year":"2001"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1365-2710.2001.00368.x","article-title":"DNA topoisomerases as targets for anticancer drugs","volume":"26","author":"Topcu","year":"2001","journal-title":"Journal of Clinical Pharmacy and Therapeutic"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/10245330701562535","article-title":"Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance","volume":"12","author":"Baran","year":"2007","journal-title":"Hematology"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0167-4781(95)00180-8","article-title":"Mammalian mitochondrial DNA topoisomerase I preferentially relaxes supercoils in plasmids containing specific mitochondrial DNA sequences","volume":"1264","author":"Topcu","year":"1995","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB23|cit23","first-page":"19","article-title":"An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids","volume":"5","author":"Sobhani","year":"2002","journal-title":"Journal of Pharmacy and Pharmaceutical Sciences"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.18388\/abp.2000_4001","article-title":"Densitometric quantification of DNA topoisomers in ethidium bromide-stained agarose gels and chemiluminescence-detected X ray films","volume":"47","author":"Topcu","year":"2000","journal-title":"Acta Biochimica Polonical"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1016\/S0021-9258(19)70730-3","article-title":"Decatenation of kinetoplast DNA by topoisomerases","volume":"255","author":"Marini","year":"1980","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","article-title":"DNA topoisomerase poisons as antitumor drugs","volume":"58","author":"Liu","year":"1989","journal-title":"Annual Review of Biochemistry"},{"key":"10.1111\/j.1365-2710.2010.01224.x-BIB27|cit27","first-page":"371","volume-title":"DNA topology and its biological effects","author":"Cozzarelli","year":"1990"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2010.01224.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2010.01224.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:59Z","timestamp":1671818639000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2010.01224.x"}},"subtitle":["Activity evaluation of imatinib"],"short-title":[],"issued":{"date-parts":[[2010,11,24]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2010.01224.x","relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11,24]]}}}